Asco 2025: phase iii aranote post-hoc analyses presented on health-related quality of life and pain outcomes in patients with metastatic castration-sensitive prostate cancer receiving nubeqa® (darolutamide) plus adt

Whippany, n.j.--(business wire)--new post-hoc analyses from the investigational phase iii aranote trial showed a clinically meaningful improvement in health-related quality of life (hrqol) and delayed pain progression for metastatic castration-sensitive prostate cancer (mcspc) patients treated with nubeqa® (darolutamide) plus androgen deprivation therapy (adt) versus patients treated with placebo plus adt.1 the results will be presented at the 2025 american society of clinical oncology (asco) a.
ADT Ratings Summary
ADT Quant Ranking